Recent Finacing
Recent Raise
Affinium Pharmaceuticals develops anti-infective drugs targeting the bacterial FASII pathway; lead candidate AFN-1252 inhibits staphylococcal FabI and is in oral phase 2 trials with IV formulations entering phase 1.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
